At a glance
ClinicalIndex Comparison RecordN/ACompleted· 73 enrolled
Drug / intervention
Red blood cell exchange in sickle celldevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.
In Brief
A clinical study evaluating Red blood cell exchange in sickle cell for Sickle Cell Disease. Completed, enrolled 73 participants across 5 sites.
Detailed Summary
The purpose of this study is to evaluate the performance of the Spectra Optia system red blood cell exchange (RBCx) protocols (exchange and depletion/exchange) in study participants with sickle cell disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedNov 29, 2012
Enrollment StartNov 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.6 years ago
Interventions
Red blood cell exchange in sickle celldevice
One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient